Although there is evidence to suggest that SGLT2 inhibitors do benefit individuals with HFrEF, none of the aforementioned studies were specifically designed to evaluate diastolic function or HFpEF, which is highly relevant when considering the impact of this drug-class on T2DM subjects with diabetic cardiomyopathy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.